Upfront triple therapy with parenteral prostanoid as a bridge to balloon pulmonary angioplasty in severe chronic...

Area of Science:

• Cardiology
• Pulmonary Medicine
• Vascular Surgery

Background:

• Chronic thromboembolic pulmonary hypertension (CTEPH) is a severe condition characterized by persistent pulmonary hypertension due to unresolved blood clots in the pulmonary arteries.
• Patients with very severe CTEPH often have limited treatment options and poor prognoses.
• Balloon pulmonary angioplasty (BPA) is a recognized intervention for CTEPH, but its effectiveness in the most severe cases, especially in combination with medical therapy, requires further investigation.

Purpose of the Study:

• To evaluate the efficacy of upfront triple pulmonary hypertension (PH) therapy, including epoprostenol, followed by balloon pulmonary angioplasty (BPA), in patients with very severe CTEPH.
• To assess the haemodynamic improvements achieved with this combined therapeutic strategy.
• To determine the feasibility and safety of performing BPA after initiating intensive medical management.

Main Methods:

• A cohort of patients with very severe CTEPH, deemed eligible for BPA, was treated with an upfront triple PH therapy regimen.
• The regimen included the prostacyclin analogue epoprostenol, alongside other PH medications.
• Following stabilization with medical therapy, patients underwent BPA procedures.

Main Results:

• The combined strategy of upfront triple PH therapy and subsequent BPA resulted in major haemodynamic improvement in patients with very severe CTEPH.
• Significant reductions in pulmonary vascular resistance and improvements in cardiac output were observed.
• The treatment approach was feasible and well-tolerated in this high-risk patient group.

Conclusions:

• Upfront triple PH therapy, incorporating epoprostenol, followed by BPA, is a successful strategy for managing very severe CTEPH.
• This approach can lead to substantial haemodynamic benefits, offering a new therapeutic avenue for patients previously considered inoperable or refractory to standard treatments.
• Further research is warranted to optimize treatment protocols and long-term outcomes.